CAI
Price
$28.30
Change
-$0.05 (-0.18%)
Updated
Oct 2 closing price
Capitalization
8.97B
40 days until earnings call
Intraday BUY SELL Signals
GMAB
Price
$34.75
Change
+$0.20 (+0.58%)
Updated
Oct 2 closing price
Capitalization
21.54B
34 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CAI vs GMAB

CAI vs GMAB Comparison Chart in %
View a ticker or compare two or three
VS
CAI vs. GMAB commentary
Oct 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CAI is a Buy and GMAB is a Buy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
CAI vs GMAB: Fundamental Ratings
CAI
GMAB
OUTLOOK RATING
1..100
440
VALUATION
overvalued / fair valued / undervalued
1..100
1
Undervalued
84
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
4659
PRICE GROWTH RATING
1..100
3639
P/E GROWTH RATING
1..100
119
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CAI's Valuation (1) in the Finance Or Rental Or Leasing industry is significantly better than the same rating for GMAB (84) in the null industry. This means that CAI’s stock grew significantly faster than GMAB’s over the last 12 months.

CAI's Profit vs Risk Rating (100) in the Finance Or Rental Or Leasing industry is in the same range as GMAB (100) in the null industry. This means that CAI’s stock grew similarly to GMAB’s over the last 12 months.

CAI's SMR Rating (46) in the Finance Or Rental Or Leasing industry is in the same range as GMAB (59) in the null industry. This means that CAI’s stock grew similarly to GMAB’s over the last 12 months.

CAI's Price Growth Rating (36) in the Finance Or Rental Or Leasing industry is in the same range as GMAB (39) in the null industry. This means that CAI’s stock grew similarly to GMAB’s over the last 12 months.

GMAB's P/E Growth Rating (9) in the null industry is in the same range as CAI (11) in the Finance Or Rental Or Leasing industry. This means that GMAB’s stock grew similarly to CAI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CAIGMAB
RSI
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
59%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
71%
Momentum
ODDS (%)
Bearish Trend 2 days ago
71%
Bullish Trend 2 days ago
57%
MACD
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
67%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
73%
Bearish Trend 2 days ago
71%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
9%
Bullish Trend 2 days ago
63%
Advances
ODDS (%)
Bullish Trend 9 days ago
65%
Bullish Trend 3 days ago
63%
Declines
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 23 days ago
70%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
67%
Bullish Trend 2 days ago
70%
Aroon
ODDS (%)
Bullish Trend 2 days ago
39%
Bullish Trend 2 days ago
63%
COMPARISON
Comparison
Oct 03, 2026
Stock price -- (CAI: $28.35 vs. GMAB: $34.55)
Brand notoriety: CAI and GMAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CAI: 77% vs. GMAB: 255%
Market capitalization -- CAI: $8.97B vs. GMAB: $21.54B
CAI [@Biotechnology] is valued at $8.97B. GMAB’s [@Biotechnology] market capitalization is $21.54B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CAI’s FA Score shows that 2 FA rating(s) are green while GMAB’s FA Score has 1 green FA rating(s).

  • CAI’s FA Score: 2 green, 3 red.
  • GMAB’s FA Score: 1 green, 4 red.
According to our system of comparison, CAI is a better buy in the long-term than GMAB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CAI’s TA Score shows that 2 TA indicator(s) are bullish while GMAB’s TA Score has 5 bullish TA indicator(s).

  • CAI’s TA Score: 2 bullish, 6 bearish.
  • GMAB’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, GMAB is a better buy in the short-term than CAI.

Price Growth

CAI (@Biotechnology) experienced а -12.15% price change this week, while GMAB (@Biotechnology) price change was -0.80% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.63%. For the same industry, the average monthly price growth was -14.35%, and the average quarterly price growth was -1.64%.

Reported Earning Dates

CAI is expected to report earnings on Nov 11, 2026.

GMAB is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (-3.63% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
CAI
Daily Signal:
Gain/Loss:
GMAB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
ELF.X0.0767660.008108
+11.81%
aelf cryptocurrency
FIRO.X1.1290700.025853
+2.34%
Firo cryptocurrency
AERGO.X0.0095810.000217
+2.32%
Aergo cryptocurrency
TCT.X0.0014070.000026
+1.90%
Tectum Cash Token cryptocurrency
PENDLE.X2.374952-0.008317
-0.35%
Pendle cryptocurrency

CAI and

Correlation & Price change

A.I.dvisor indicates that over the last year, CAI has been loosely correlated with BMEA. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if CAI jumps, then BMEA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CAI
1D Price
Change %
CAI100%
-7.44%
BMEA - CAI
38%
Loosely correlated
-2.26%
RXRX - CAI
34%
Loosely correlated
-1.45%
TWST - CAI
34%
Loosely correlated
-2.69%
GMAB - CAI
33%
Loosely correlated
-3.15%
TECH - CAI
33%
Poorly correlated
-0.10%
More

GMAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, GMAB has been loosely correlated with AXON. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if GMAB jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GMAB
1D Price
Change %
GMAB100%
-3.15%
AXON - GMAB
47%
Loosely correlated
-0.07%
LKFT - GMAB
41%
Loosely correlated
-2.66%
RYTM - GMAB
40%
Loosely correlated
-1.90%
EXEL - GMAB
38%
Loosely correlated
-0.80%
HALO - GMAB
38%
Loosely correlated
-3.13%
More